Regulation of Cardiovascular Control Mechanisms by Angiotensin-(1–7) and Angiotensin-Converting Enzyme 2

Ferrario, Carlos M.; Averill, David B.; Brosnihan, K. Bridget; Chappell, Mark C.; Diz, Debra I.; Gallagher, Patricia E.; Neves, Liomar A. A.; Tallant, E. Ann

doi:10.1007/978-1-59259-987-5_3

Hypertension and Hormone Mechanisms 2007

DOI: 10.1007/978-1-59259-987-5_3

|View full text |Cite

Regulation of Cardiovascular Control Mechanisms by Angiotensin-(1–7) and Angiotensin-Converting Enzyme 2

Carlos M. Ferrario

David B. Averill

K. Bridget Brosnihan

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2009

Publication Types

Select...

Article1

Relationship

Self Cite1

Independent0

Authors

Journals

Cited by 1 publication

(2 citation statements)

References 99 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Local tissue renin-angiotensin systems also exist and are involved in a variety of autocrine, intracrine, and paracrine functions (1, 2). The eight–amino acid peptide angiotensin II (Ang II), a major effector hormone of the system, is a potent vasoconstrictor and mitogen, whereas angiotensin-(1-7) [Ang-(1-7)] produces unique physiologic responses that often oppose Ang II actions (1-3). Ang-(1-7) is present in the circulation and tissues at concentrations similar to Ang II and functions as a vasodilator with antiproliferative and antiangiogenic properties (4).…”

mentioning

confidence: 99%

See 1 more Smart Citation

Phase I and Pharmacokinetic Study of Angiotensin-(1-7), an Endogenous Antiangiogenic Hormone

Petty

Miller

McCoy

et al. 2009

Clinical Cancer Research

Self Cite

View full text Add to dashboard Cite

Purpose Angiotensin-(1-7) [Ang-(1-7)] is an endogenous peptide hormone of the reninangiotensin system with antiproliferative and antiangiogenic properties. The primary objective of this study was to establish the recommended phase II dose of Ang-(1-7) for treating patients with advanced cancer. Secondary objectives were to assess toxicities, pharmacokinetics, clinical activity, and plasma biomarkers. Experimental Design Patients with advanced solid tumors refractory to standard therapy were treated with escalating doses of Ang-(1-7) in cohorts of three patients. Ang-(1-7) was administered by s.c. injection once daily for 5 days on a 3-week cycle. Tumor measurements were done every two cycles and treatment was continued until disease progression or unacceptable toxicity. Results Eighteen patients were enrolled. Dose-limiting toxicities encountered at the 700 μg/kg dose included stroke (grade 4) and reversible cranial neuropathy (grade 3). Other toxicities were generally mild. One patient developed a 19% reduction in tumor measurements. Three additional patients showed clinical benefit with stabilization of disease lasting more than 3 months. On day 1, Ang-(1-7) administration led to a decrease in plasma placental growth factor (PlGF) levels in patients with clinical benefit (P = 0.04) but not in patients without clinical benefit (P = 0.25). On day 5, PlGF levels remained lower in patients with clinical benefit compared with patients without clinical benefit (P = 0.04). Conclusions Ang-(1-7) is a first-in-class antiangiogenic drug with activity for treating cancer that is linked to reduction of plasma PlGF levels. The recommended phase II dose is 400 μg/kg for this administration schedule.

show abstract

mentioning

confidence: 99%

“…Both Ang II and Ang-(1-7) mediate their biological effects through interaction with distinct, high-affinity angiotensin receptors to activate molecular signaling pathways. Ang II is an agonist for the Ang II type 1 and type 2 receptors, whereas Ang-(1-7) activates the unique G protein–coupled receptor mas (1-5). …”

mentioning

confidence: 99%

Phase I and Pharmacokinetic Study of Angiotensin-(1-7), an Endogenous Antiangiogenic Hormone

Petty

Miller

McCoy

et al. 2009

Clinical Cancer Research

Self Cite

View full text Add to dashboard Cite

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Regulation of Cardiovascular Control Mechanisms by Angiotensin-(1–7) and Angiotensin-Converting Enzyme 2

Cited by 1 publication

References 99 publications

Phase I and Pharmacokinetic Study of Angiotensin-(1-7), an Endogenous Antiangiogenic Hormone

Phase I and Pharmacokinetic Study of Angiotensin-(1-7), an Endogenous Antiangiogenic Hormone

Contact Info

Product

Resources

About